Neuroblastoma: Diagnostic and Clinical Aspects

Abstract

Due to its many clinical and biologic characteristics, neuroblastoma (NB) is a polyhedric neoplasm. It is a very complex, extremely heterogeneous disease that can regress spontaneously even without therapy. However, it frequently shows a very aggressive behavior, refractory to current intensive multimodal therapy. The tumor, originating from primordial neural crest cells, is biochemically unique for its metabolic pathways of catecholamine synthesis and metabolism. Homovanillic acid (HVA), the main metabolite of dopamine, and vanillylmandelic acid (VMA), the main metabolite of adrenalin and noradrenalin, are sensitive and convenient markers of NB since they are found in large amounts in patient's urine. The rate of NB patients with positive VMA and/or HVA at the diagnosis varies with the stage of the disease, with high-stage tumors being more likely to have abnormal levels. Other less specific NB tumor serum markers are neuron-specific enolase, ferritin, and lactate dehydrogenase. NB is one of the few pediatric tumors in which tumor markers have been shown to have a role in the diagnosis, prognosis, and disease monitoring.

Keywords

neuroblastoma - homovanillic acid - vanillylmandelic acid - neuron-specific enolase - ferritin - lactate dehydrogenase

• References

• 1 Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010; 24 (1) 65-86
• 2 Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3 (3) 203-216
• 3 Navarro S, Piqueras M, Villamón E , et al. New prognostic markers in neuroblastoma. Expert Opin Med Diagn 2012; 6 (6) 555-567
• 4 Virchow R. Hyperplasie der Zirbel und der Nebennieren. In: Die Krankhaften Geschwulste. Vol. 2. Berlin: Hirschwald; 1864
• 5 Rothenberg AB, Berdon WE, D'Angio GJ, Yamashiro DJ, Cowles RA. Neuroblastoma-remembering the three physicians who described it a century ago: James Homer Wright, William Pepper, and Robert Hutchison. Pediatr Radiol 2009; 39 (2) 155-160
• 6 Hinterberger H, Bartholomew RJ. Catecholamines and their acidic metabolites in urine and in tumour tissue in neuroblastoma, ganglioneuroma and phaeochromocytoma. Clin Chim Acta 1969; 23 (1) 169-175
• 7 Bolkar ST, Ghadge MS, Raste AS. Biochemical parameters in neuroblastoma. Indian J Clin Biochem 2008; 23 (3) 293-295
• 8 Conte M, Parodi S, De Bernardi B , et al. Neuroblastoma in adolescents: the Italian experience. Cancer 2006; 106 (6) 1409-1417
• 9 Gigliotti AR, Di Cataldo A, Sorrentino S , et al. Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry. Eur J Cancer 2009; 45 (18) 3220-3227
• 10 Shimada H, Umehara S, Monobe Y , et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001; 92 (9) 2451-2461
• 11 Verloes A, Elmer C, Lacombe D , et al. Ondine-Hirschsprung syndrome (Haddad syndrome). Further delineation in two cases and review of the literature. Eur J Pediatr 1993; 152 (1) 75-77
• 12 Maris JM, Chatten J, Meadows AT, Biegel JA, Brodeur GM. Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease. Med Pediatr Oncol 1997; 28 (1) 1-5
• 13 Maris JM, Brodeur GM. Genetics of neuroblastoma. In: Cowell JK, ed. Molecular Genetics of Cancer. 2nd ed. Oxford: BIOS; 2001: 335-361
• 14 Origone P, Defferrari R, Mazzocco K, Lo Cunsolo C, De Bernardi B, Tonini GP. Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. Am J Med Genet A 2003; 118A (4) 309-313
• 15 Martinsson T, Sjöberg RM, Hedborg F, Kogner P. Homozygous deletion of the neurofibromatosis-1 gene in the tumor of a patient with neuroblastoma. Cancer Genet Cytogenet 1997; 95 (2) 183-189
• 16 Satgé D, Moore SW, Stiller CA , et al. Abnormal constitutional karyotypes in patients with neuroblastoma: a report of four new cases and review of 47 others in the literature. Cancer Genet Cytogenet 2003; 147 (2) 89-98
• 17 Blatt J, Olshan AF, Lee PA, Ross JL. Neuroblastoma and related tumors in Turner's syndrome. J Pediatr 1997; 131 (5) 666-670
• 18 Satgé D, Sasco AJ, Carlsen NL , et al. A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res 1998; 58 (3) 448-452
• 19 Schwab M, Alitalo K, Klempnauer KH , et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983; 305 (5931) 245-248
• 20 Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A 1984; 81 (15) 4940-4944
• 21 Katzenstein HM, Bowman LC, Brodeur GM , et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience—a pediatric oncology group study. J Clin Oncol 1998; 16 (6) 2007-2017
• 22 Canete A, Gerrard M, Rubie H , et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol 2009; 27 (7) 1014-1019
• 23 Rubie H, De Bernardi B, Gerrard M , et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol 2011; 29 (4) 449-455
• 24 De Bernardi B, Gerrard M, Boni L , et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009; 27 (7) 1034-1040
• 25 Nickerson HJ, Matthay KK, Seeger RC , et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 2000; 18 (3) 477-486
• 26 Rubie H, Hartmann O, Michon J , et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol 1997; 15 (3) 1171-1182
• 27 Ozer E, Altungoz O, Unlu M, Aygun N, Tumer S, Olgun N. Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity. Appl Immunohistochem Mol Morphol 2007; 15 (2) 181-186
• 28 Goto S, Umehara S, Gerbing RB , et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001; 92 (10) 2699-2708
• 29 Theissen J, Oberthuer A, Hombach A , et al. Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma. Genes Chromosomes Cancer 2014; 53 (8) 639-649
• 30 Cheung N-KV, Cohn SL. Neuroblastoma: Pediatric Oncology. Berlin: Springer; 2005
• 31 Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997; 28 (4) 284-288
• 32 Rudnick E, Khakoo Y, Antunes NL , et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001; 36 (6) 612-622
• 33 Cooper R, Khakoo Y, Matthay KK , et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 2001; 36 (6) 623-629
• 34 El Shafie M, Samuel D, Klippel CH, Robinson MG, Cullen BJ. Intractable diarrhea in children with VIP-secreting ganglioneuroblastomas. J Pediatr Surg 1983; 18 (1) 34-36
• 35 Lilling G, Wollman Y, Goldstein MN , et al. Inhibition of human neuroblastoma growth by a specific VIP antagonist. J Mol Neurosci 1994– 1995; 5 (4) 231-239
• 36 Sendo D, Katsuura M, Akiba K , et al. Severe hypertension and cardiac failure associated with neuroblastoma: a case report. J Pediatr Surg 1996; 31 (12) 1688-1690
• 37 Chauty A, Raimondo G, Vergeron H , et al. Discovery of a neuroblastoma producing cardiogenic shock in a 2-month-old child [in French]. Arch Pediatr 2002; 9 (6) 602-605
• 38 Kwok SY, Cheng FW, Lo AF, Leung WK, Yam MC, Li CK. Variants of cardiomyopathy and hypertension in neuroblastoma. J Pediatr Hematol Oncol 2014; 36 (3) e158-e161
• 39 de Grauw AM, Mul D, van Noesel MM, Buddingh EP. Stress hyperglycaemia as a result of a catecholamine producing tumour in an infant. BMJ Case Rep 2015; . doi:10.1136/bcr-2014-209091
• 40 Brodeur GM, Pritchard J, Berthold F , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11 (8) 1466-1477
• 41 Pritchard J, Barnes J, Germond S , et al; European Neuroblastoma Study Group. Stage and urinary catecholamine metabolite excretion in neuroblastoma. Lancet 1989; 2 (8661) 514-515
• 42 LaBrosse EH, Com-Nougué C, Zucker JM , et al. Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors. Cancer Res 1980; 40 (6) 1995-2001
• 43 Monsaingeon M, Perel Y, Simonnet G, Corcuff JB. Comparative values of catecholamines and metabolites for the diagnosis of neuroblastoma. Eur J Pediatr 2003; 162 (6) 397-402
• 44 Strenger V, Kerbl R, Dornbusch HJ , et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer 2007; 48 (5) 504-509
• 45 Davidson DF. Simultaneous assay for urinary 4-hydroxy-3-methoxy-mandelic acid, 5-hydroxyindoleacetic acid and homovanillic acid by isocratic HPLC with electrochemical detection. Ann Clin Biochem 1989; 26 (Pt 2) 137-143
• 46 Allenbrand R, Garg U. Quantitation of homovanillic acid (HVA) and vanillylmandelic acid (VMA) in urine using gas chromatography-mass spectrometry (GC/MS). Methods Mol Biol 2010; 603: 261-269
• 47 Hsu WY, Chen CM, Tsai FJ, Lai CC. Simultaneous detection of diagnostic biomarkers of alkaptonuria, ornithine carbamoyltransferase deficiency, and neuroblastoma disease by high-performance liquid chromatography/tandem mass spectrometry. Clin Chim Acta 2013; 420: 140-145
• 48 Shi RZ, Ho YP, Yeung JH , et al. Development of an enzyme-linked immunosorbent assay with monoclonal antibody for quantification of homovanillic acid [corrected] in human urine samples. Clin Chem 1998; 44 (8, Pt 1) 1674-1679
• 49 Tuchman M, Robison LL, Maynard RC, Ramnaraine ML, Krivit W. Assessment of the diurnal variations in urinary homovanillic and vanillylmandelic acid excretion for the diagnosis and follow-up of patients with neuroblastoma. Clin Biochem 1985; 18 (3) 176-179
• 50 Gregianin LJ, McGill AC, Pinheiro CM, Brunetto AL. Vanilmandelic acid and homovanillic acid levels in patients with neural crest tumor: 24-hour urine collection versus random sample. Pediatr Hematol Oncol 1997; 14 (3) 259-265
• 51 Cangemi G, Barco S, Reggiardo G , et al. Interchangeability between 24-hour collection and single spot urines for vanillylmandelic and homovanillic acid levels in the diagnosis of neuroblastoma. Pediatr Blood Cancer 2013; 60 (12) E170-E172
• 52 Barco S, Gennai I, Reggiardo G , et al. Urinary homovanillic and vanillylmandelic acid in the diagnosis of neuroblastoma: report from the Italian Cooperative Group for Neuroblastoma. Clin Biochem 2014; 47 (9) 848-852
• 53 Di Cataldo A, Dau D, Conte M , et al; Italian Cooperative Group for Neuroblastoma. Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma. Med Sci Monit 2009; 15 (1) MT11-MT18
• 54 Hann HW, Bombardieri E, Serum markers and prognosis in neuroblastoma: Ferritin, LDH, NSE. In: Brodeur G, Sawada T, Tsuchida Y, Voute PA. eds. Neuroblastoma. Amsterdam: Elsevier; 2000: 371-381
• 55 Simon T, Hero B, Hunneman DH, Berthold F. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer 2003; 39 (13) 1899-1903
• 56 Zeltzer PM, Marangos PJ, Parma AM , et al. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet 1983; 2 (8346) 361-363
• 57 Hann HW, Evans AE, Siegel SE , et al. Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res 1985; 45 (6) 2843-2848
• 58 Berthold F, Kassenböhmer R, Zieschang J. Multivariate evaluation of prognostic factors in localized neuroblastoma. Am J Pediatr Hematol Oncol 1994; 16 (2) 107-115
• 59 Berthold F, Trechow R, Utsch S, Zieschang J. Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. Am J Pediatr Hematol Oncol 1992; 14 (3) 207-215
• 60 Shuster JJ, McWilliams NB, Castleberry R , et al. Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. Am J Clin Oncol 1992; 15 (4) 295-303
• 61 Lau L. Neuroblastoma: a single institution's experience with 128 children and an evaluation of clinical and biological prognostic factors. Pediatr Hematol Oncol 2002; 19 (2) 79-89
• 62 Cangemi G, Reggiardo G, Barco S , et al. Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. Onco Targets Ther 2012; 5: 417-423
• 63 Geatti O, Shapiro B, Sisson JC , et al. Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med 1985; 26 (7) 736-742
• 64 Voute PA, Hoefnagel CA, Marcuse HR, de Kraker J. Detection of neuroblastoma with 131I-meta-iodobenzylguanidine. Prog Clin Biol Res 1985; 175: 389-398
• 65 Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003; 21 (6) 1082-1086
• 66 Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19 (14) 3397-3405
• 67 Scanga DR, Martin WH, Delbeke D. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med 2004; 29 (2) 86-90
• 68 Monclair T, Brodeur GM, Ambros PF , et al; INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27 (2) 298-303
• 69 Cecchetto G, Mosseri V, De Bernardi B , et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005; 23 (33) 8483-8489
• 70 Dubois SG, London WB, Zhang Y , et al. Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer 2008; 51 (5) 589-592
• 71 Mossé YP, Laudenslager M, Longo L , et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455 (7215) 930-935
• 72 Haupt R, Garaventa A, Gambini C , et al. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J Clin Oncol 2010; 28 (14) 2331-2338